Bliss GVS Pharma Limited reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported sales was INR 2,162.58 million compared to INR 1,640.61 million a year ago. Revenue was INR 2,222.94 million compared to INR 1,681.77 million a year ago. Net loss was INR 501.12 million compared to net income of INR 255.51 million a year ago. Basic loss per share from continuing operations was INR 4.83 compared to basic earnings per share from continuing operations of INR 2.48 a year ago.
For the nine months, sales was INR 5,803.91 million compared to INR 4,451.52 million a year ago. Revenue was INR 5,996.94 million compared to INR 4,590.5 million a year ago. Net loss was INR 45.92 million compared to net income of INR 622.49 million a year ago. Basic loss per share from continuing operations was INR 0.44 compared to basic earnings per share from continuing operations of INR 6.03 a year ago.